← Who reports today · Health Care
EW · Q2 2026
Archived report (Q2 2026). Latest deep dive →
The quarter in brief
Revenue grew 13.6% y/y to $1.74B, operating margin 29.5% vs 26.8%, net income $242M (−27.4% y/y).
Net income attributable to Edwards Lifesciences Corporation
$242M
down 27.4% y/y
Net sales
$1,741M
up 13.6% y/y
Operating income, net
$513M
up 24.8% y/y
Gross profit
$1,349M
up 13.5% y/y
All figures in $M.
| Line item | Amount and change |
|---|---|
| Net sales | $1,741 · +13.6% |
| Cost of sales | $392 · +13.9% |
| Gross profit | $1,349 · +13.5% · 77.5% margin |
| Selling, general, and administrative expenses | $561 · +11.8% |
| Research and development expenses | $279 · +1.0% |
| Certain litigation expenses | $6.3 · −59.4% |
| Other operating income | $11 · −48.4% |
| Operating income, net | $513 · +24.8% · 29.5% margin |
| Interest income, net | $30 · −19.8% |
| Loss on impairment | $40 · −15.1% |
| Other non-operating (income) expense, net | $16.6 · vs −$1.3 |
| Income from continuing operations before provision for income taxes | $520 · +29.9% |
| Provision for income taxes | $278 · +333% · 53.6% effective rate |
| Net loss attributable to noncontrolling interest | $0.5 · −70.6% |
| Net income attributable to Edwards Lifesciences Corporation | $242 · −27.4% · $0.42/sh · 13.9% margin |
Verdict: revenue grew 13.6% y/y to $1.74B, operating margin 29.5% vs 26.8%, net income $242M (−27.4% y/y).
Source and notation
Source: Edwards Lifesciences press release, 8-K EX-99.1 of 07/23/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.
Open as an image: EW, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “EW Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/ew/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/ew/q2-2026"><img src="https://whoreportstoday.com/t/ew/q2-2026/sankey.png" alt="EW Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/ew/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/ew/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/ew/q2-2026">EW Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Gross margin was 77.5% vs 77.5% a year earlier.
- Operating income was $513M, a 29.5% margin vs 26.8% a year earlier.
- The effective tax rate was 53.6% vs 16.1% a year earlier.
- Diluted EPS was $0.42 vs $0.56 a year earlier.
What distorts the picture in this report and what to watch beyond the headlines.
EW — a medical device company focused on structural heart disease that makes transcatheter and surgical technologies to replace and repair aortic, mitral and tricuspid heart valves.
It sells to hospitals and is managed in four geographic segments: United States, Europe, Japan and Rest of World. · Source: annual report (Form 10-K, SEC)
Heads-up
- net income fell 27% y/y in Q2 2026
Net income for Q2 2026: $242M, −27% y/y. In the report's figures: costs grew faster than revenue: provision for income taxes +333% y/y. Based on the Q2 2026 report.
The company's report ↗More reports: GEHC · Q3 2026 · GILD · Q3 2026 · HCA · Q3 2026 · HSIC · Q3 2026 · HUM · Q2 2026 · IDXX · Q3 2026 · ILMN · Q3 2026 · INCY · Q2 2026 · IQV · Q3 2026 · ISRG · Q3 2026 · all reports